Disease activity and prognostic factors in juvenile dermatomyositis: A long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1578-1585

  Sanner, Helga ^a,b   Sjaastad, Ivar ^a,c,d   Flatø, Berit ^a,d  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Adolescent rheumatology; Dermatomyositis; Disease activity; Myositis; Outcome measures; Outcomes research; Paediatric rheumatology

Indexed keywords

ANTIMALARIAL AGENT; CYCLOSPORIN A; INFLIXIMAB; MUSCLE ENZYME; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CALCINOSIS; CHILD; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL; PEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANIZATION CRITERIA FOR INACTIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SHORT FORM 36;

EID: 84906827500     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu146     Document Type: Article

References (32)

1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
2. Ravelli A, Trail L, Ferrari C et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63-72.
3. Rider LG, Lachenbruch PA, Monroe JB et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009;60:3425-35.
4. Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology 2009;48:1541-7.
5. Mathiesen P, Hegaard H, Herlin T et al. Long-term outcome in patients with juvenile dermatomyositis: a crosssectional follow-up study. Scand J Rheumatol 2012;41: 50-8.
6. Ruperto N, Ravelli A, Pistorio A et al. The provisional Paediatric Rheumatology International Trials Organisation/ American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13.
7. Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43:49-54.
8. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15.
9. Kim S, El-Hallak M, Dedeoglu F et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009;60: 1825-30.
10. Oddis CV, Rider LG, Reed AM et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52: 2607-15.
11. Lazarevic D, Pistorio A, Palmisani E et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013;72:686-93.
12. Luca NJ, Feldman BM. Paediatric rheumatic disease: defining clinically inactive disease in juvenile dermatomyositis. Nat Rev Rheumatol 2012;8:638-9.
13. Sanner H, Kirkhus E, Merckoll E et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res 2010;62:1103-11.
14. Sanner H, Aalokken TM, Gran JT et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:86-91.
15. Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I. Cardiac dysfunction in juvenile dermatomyositis: a casecontrol study. Ann Rheum Dis 2011;70:766-71.
16. Schwartz T, Sanner H, Gjesdal O, Flato B, Sjaastad I. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 2013; Advance Access published 23 July 2013, doi: 10.1136/ annrheumdis-2013-203279.
17. Tollisen A, Sanner H, Flato B, Wahl AK. Quality of life in adults with juvenile onset dermatomyositis-a case control study. Arthritis Care Res 2012;64:1020-27.
18. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
19. Sultan SM, Allen E, Oddis CV et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008;58:3593-9.
20. Rider LG, Werth VP, Huber AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 2011;63(Suppl 11):S118-57.
21. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
22. Rider LG, Koziol D, Giannini EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465-72.
23. Lovell DJ, Lindsley CB, Rennebohm RM et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999;42: 2213-9.
24. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
25. Feldman BM, Ayling-Campos A, Luy L et al. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995;22:326-31.
26. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998;26:250-8.
27. Ware JE Jr, Kosinski MA. Physical and Mental Summary Scales: A Manual for Users of Version 1. Lincoln, RI: Quality Metric, 2001.
28. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983;103:882-8.
29. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58: 3585-92.
30. Mamyrova G, O'Hanlon TP, Monroe JB et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006;54: 3979-87.
31. Pachman LM, Abbott K, Sinacore JM et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006;148:247-53.
32. Rider LG, Giannini EH, Harris-Love M et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17.